DEA's cannabis rescheduling hearing is over. The stage is set for a court battle.

OH, DEA
The DEA's cannabis rescheduling hearing is over. The stage is set for a court battle.

Arlington, VA: The cannabis rescheduling hearings wrapped up in Virginia last week and may have set the stage for a bigger fight to come. 

The historic hearings that took place over the last two weeks were to decide whether the DEA can continue with its plan to move cannabis from Schedule I to Schedule III, a far less restrictive category under the Controlled Substances Act. But they were also an opportunity to build the case for future appeals, should Chief Administrative Law Judge Derek Julius rule in favor of rescheduling. Stakeholders on both sides of the argument say the hearings themselves have set the stage for a complicated future lawsuit.  

Key testimony from government representatives at the hearing gave proponents something to be nervous about and opponents new ammunition in their argument against rescheduling. Pro-rescheduling supporters, however, still believe their case can withstand the new information.

“Dr. [Dominic] Chiapperino’s testimony is going to support the government's argument that this process was measured, it was robust, it was thoughtful,” said Kelly Fair, a principal and strategic partner at Crestwood Strategies, referencing testimony given by the Director of the FDA’s Controlled Substances Staff on the first day of the hearing.

At the Administrative Law Judge hearing, two primary questions were at stake: is there any indication for medical usefulness, and how large is the potential for abuse? 

The DEA is legally bound to defend HHS’ report and did so with simple efficiency, often spending far less time questioning and cross-examining witnesses than the anti-rescheduling opposition. 

The anti-rescheduling opposition, meanwhile, worked hard to build a legal record that could help in future legal challenges. They brought law enforcement, medical professionals, families of people impacted by cannabis use, government scientists and more to the stand to build a case of abuse potential and to question the government’s decision to use a new, two-part test for medical use potential. 

Both sides, unsurprisingly, feel bullish about their chances that Judge Julius rules in their favor. At the same time, both are looking to testimony presented during the hearings to bolster their case in a possible lawsuit to come after the government makes a final decision.

LIT ALERTS
Illinois Cannabis Market Heating Up: Meet the Challenger Brands Taking Market Share

While legacy MSO brands hold shelf space, a new wave of challenger brands is rapidly reshaping the Illinois market through multi-category expansion, high-potency infusions, and strain-specific transparency.

Daze Off is leading the charge — dominating Flower, Pre-Rolls, and Edibles simultaneously. Meanwhile, brands like Aeriz, Honor Roll, Rove, and Nature's Heritage are capturing disproportionate momentum in their respective categories by doubling down on what Illinois consumers actually want: potent infusions, whole-flower commitments, and authentic strain profiles.

Lit Alerts’ data from April–July 2026 reveals which brands are truly winning the Illinois market.

Read the full breakdown on Lit Alerts »